Applying HiFi sequencing as a first-tier assay is designed to consolidate and simplify the laboratory workflow especially in the context of post-mortem tissue and newborn dried blood spots as challenging sample inputs.

What Is Actually Changing In PacBio’s Fair Value Story? Analysts have lifted their fair value estimate for Pacific Biosciences of California from US$2.36 to US$2.50, a move that sits on a small set of updated assumptions rather than any sweeping change in the story.

Pacific Biosciences of California (PACB) announced preliminary Q4 2025 revenue of $44.6M, up 14% year over year, vs estimate of $42M. Full-year 2025 revenue is expected to be $160M, representing 4% growth Y/Y,

PACB is gaining from product development and strong Q3 results, with Revio and Vega driving growth, though longer purchasing cycles remain a risk.

PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced plans to pursue a strategic collaboration with the n-Lorem Foundation and EspeRare that we believe will position long-read whole-genome sequencing as enabling infrastructure to support the development of individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases.

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, announced a new community-developed method, CiFi, yesterday. It enables chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run,

PacBio CEO Christian Henry speaks on day one of the in-person meeting of American Society of Human Genetics, the first in-person since 2019 Menlo Park-based Pacific Biosciences (PacBio) kicked off the first in-person American Society of Human Genetics ...

The work is never done for Pacific Biosciences. The DNA sequencing developer declared that it has begun shipping its first short-read hardware—while simultaneously announcing a new acquisition that aims to boost those capabilities in the future.

(Reuters) - Gene-sequencing company Pacific BioSciences of California Inc on Tuesday announced the launch of a new, more affordable, higher-throughput "long-read" sequencer as well as customer testing of its first "short-read" sequencer aimed at emerging ...

As of Wednesday, December 31, Pacific Biosciences of California, Inc.’s PACB share price has surged by 5.49%, which has investors questioning if this is right time to sell.